Inflammatory Bowel Disease

>

Latest News

Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients
Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients

April 25th 2025

In a real-world study of patients with Crohn disease, upadacitinib achieved 52.1% clinical remission at 12 weeks and 42.7% endoscopic remission at 6 months, with no new safety concerns reported.

Guselkumab (Tremfya) Gains FDA Approval for Crohn Disease: Daily Dose / image credit: ©New Africa/AdobeStock
Guselkumab (Tremfya) Gains FDA Approval for Crohn Disease: Daily Dose

April 8th 2025

Guselkumab (Tremfya) Wins Approval for Crohn Disease, Fourth Indication for Immune-Mediated Diseases / image credit ©MichaelVi/stock.adobe.com
Guselkumab (Tremfya) Wins Approval for Crohn Disease, Fourth Indication for Immune-Mediated Diseases

March 21st 2025

FDA Approves Mirikizumab for Crohn Disease: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves Mirikizumab for Crohn Disease: Daily Dose

January 27th 2025

Landmark International Trial Seeks to Intercept and Prevent Crohn Disease Using Biomarkers / image credit ©rookielion/stock.adobe.com
Landmark International Trial Seeks to Intercept and Prevent Crohn Disease Using Biomarkers

January 22nd 2025

<123
© 2025 MJH Life Sciences

All rights reserved.